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Framingham and Boston, Massachusetts; and Bethesda, Maryland
Objectives We sought to determine whether impaired fasting glucose (IFG) predicts cardiovascular disease (CVD) events.
Background It is unclear which glucose threshold should define prediabetes. We compared the 1997 and 2003 American
Diabetes Association (ADA) definitions of IFG to predict CVD.
Methods Framingham offspring participants free of CVD, categorized by the 1997 ADA IFG definition (fasting plasma glu-
cose 110 to 125 mg/dl; 6.1 to 6.9 mmol/l) or the 2003 definition (100 to 125 mg/dl; 5.6 to 6.9 mmol/l), were
followed from 1983 to 2004. Pooled logistic regression was used to calculate multivariable-adjusted odds ratios
(ORs) for incident coronary heart disease (CHD; 291 events) or CVD (423 events).
Results Four-year CHD event rates among women were 1.3% (100 to 109 mg/dl), 2.3% (110 to 125 mg/dl), and 2.9%
(diabetes); whereas corresponding rates in men were 2.9%, 3.0%, and 8.7%. For the 2003 IFG definition, the OR
for CHD among women was 1.7 (95% confidence interval [CI] 1.0 to 3.0, p  0.048), whereas for the 1997 IFG
definition, the OR for CHD in women was 2.2 (95% CI 1.1 to 4.4, p  0.02), which was almost as high as for
women with diabetes (OR 2.5, 95% CI 1.2 to 5.2, p  0.01). For CVD, only the 1997 IFG definition yielded signif-
icantly greater odds of CVD in women (OR 2.1, 95% CI 1.2 to 3.6, p  0.01). Men were not at increased odds of
developing CVD or CHD by either definition.
Conclusions In women, both IFG definitions were associated with increased CHD risk, whereas neither IFG definition identified
men at increased short-term risk for CHD or CVD. The finding that women with FPG 110 to 125 mg/dl had similar
CHD risk compared with women with diabetes suggests that CHD risk in women may be elevated at a lower glucose
level than for men. (J Am Coll Cardiol 2008;51:264–70) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.09.038(
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tt has been recognized that prediabetic hyperglycemia con-
ers an increased risk for cardiovascular disease (CVD) (1,2).
n 1997, the American Diabetes Association (ADA) intro-
uced the concept of impaired fasting glucose (IFG), a
rediabetic state initially defined by fasting plasma glucose
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007, accepted September 17, 2007.FPG) of 110 to 125 mg/dl (6.1 to 6.9 mmol/l), in which
hose afflicted were significantly more likely to develop
iabetes (3–5). The risk of developing CVD was not
onsidered in establishing criteria for IFG.
Since the introduction of the concept of IFG, there has
een considerable debate regarding where the lower limit
hould be set to achieve a reasonable balance between
ensitivity and specificity for diabetes prediction. In 2003,
he ADA lowered its threshold for diagnosis of IFG from
10 mg/dl (6.0 mmol/l) to 100 mg/dl (5.6 mmol/l) on the
asis of evidence in selected samples that suggested diabetes
rediction may be optimized at a lower threshold (6). The
ffect of this lowered cut point is that a much larger
roportion of the population is now considered to have
FG. Using data from the Third National Health and
utrition Examination Survey, Benjamin et al. (7) found
hat the prevalence of IFG among adults was estimated to
ncrease from 8.3% to 30.2%.
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January 22, 2008:264–70 Impact of IFG on CVDSince the publication of the 2003 IFG guidelines, rela-
ively few studies have examined the impact of the 2003
FG definition on CVD risk, and none have found a
elation between FPG 100 to 125 mg/dl (5.6 to 6.9 mmol/l)
nd increased CVD risk or mortality (8–12). However,
hese studies have been limited by examination of samples
ith limited generalizability (9–11), relatively small samples
ith few CVD events during follow-up period (8), and
otential inclusion of participants who develop diabetes in
he IFG category (9,12).
Thus, on the basis of available data, it is uncertain
hether the 2003 ADA definition of IFG offers improved
isk prediction regarding cardiovascular disease as compared
ith the 1997 IFG definition. Therefore, the primary aims
f this analysis were to characterize the new 2003 ADA
efinition of IFG in the Framingham Offspring study by
xamining incident CVD events as compared with the 1997
FG definition. We also assessed the risk of developing
iabetes based on the 2 IFG definitions.
ethods
tudy sample. Participants for this study were drawn from
he Framingham Offspring cohort. The design and inclu-
ion criteria of the Framingham Heart Study have been
escribed elsewhere (13). The current investigation included
ffspring participants who attended examinations (referred
o as index examinations) in 1983 to 1987 (cycle 3), 1987 to
991 (cycle 4), 1991 to 1995 (cycle 5), and 1995 to 1998
cycle 6). Participants could contribute information to more
han one examination cycle provided they reached the next
xamination cycle free of an outcome event of interest. All
articipants with CHD or CVD at the index examinations
ere excluded from further analyses. Participants were
ollowed in approximately 4-year intervals, and events were
ccrued through December 31, 2004. Overall, 4,138 unique
ndividuals contributed a total of 13,273 person-exams for
nalyses of incident CHD, and 4,058 unique individuals
ontributed 12,918 person-exams for analyses of incident
VD. For analyses involving incident diabetes, a total of
,634 unique individuals free of diabetes and CHD at
aseline were followed until diabetes or examination cycle 7
1998 to 2001) contributing a total of 11,325 person-exams.
he Institutional Review Board at Boston Medical Center
pproved the study protocol, and all participants gave
ritten informed consent.
aseline measurements and definitions. All Framingham
linic visits include a physician interview, physical examina-
ion, and laboratory tests. Participants who had a fasting
lasma glucose 126 mg/dl (7.0 mmol/dl) or were on
nsulin or oral hypoglycemic agents were considered to have
iabetes. The 1997 ADA guidelines defined IFG as a FPG
oncentration of 110 to 125 mg/dl (6.1 to 6.9 mmol/l) (14),
hereas the 2003 ADA guidelines define IFG as 100 to 125
g/dl (5.6 to 6.9 mmol/l) (6). cutcome ascertainment. The
rimary outcomes of interest
ere CHD, CVD, and diabetes.
oronary heart disease included
ases of myocardial infarction,
table and unstable angina pecto-
is, and CHD death (15). Car-
iovascular disease was defined
s any CHD event, stroke, tran-
ient ischemic attack (TIA), inter-
ittent claudication, congestive
eart failure, or CVD death. Dia-
etes was defined as described pre-
iously in the previous section. A
anel of 3 physicians reviewed
ach CHD and CVD event and
djudicated the end point accord-
ng to pre-established criteria (16).
ovariates. Covariates were as-
essed and updated at all index
xaminations. Covariates included
ge, systolic blood pressure, hypertension treatment, total
holesterol to high-density lipoprotein cholesterol ratio,
igarette smoking within the past year, and body mass index
BMI). For incident diabetes, covariates were age, cigarette
moking within the past year, and BMI. Hypertension was
efined as systolic blood pressure 140 mm Hg, diastolic
lood pressure 90 mm Hg, or current treatment with
ntihypertensive medications. Current smoking was defined
s at least 1 cigarette per day within 1 year of the index
xamination. Weight, measured to the nearest pound, was
btained with the participant wearing a gown without
lippers or shoes. The BMI was calculated by dividing
eight (kilograms) by square of height (meters2).
tatistical analysis. A significant gender interaction was
bserved when age–gender-adjusted models were fit with an
FG-by-gender interaction. Therefore, all subsequent anal-
ses were gender-specific.
All individuals with CHD or CVD at each index exam-
nation were excluded. Three separate models were used to
xamine incident CHD and CVD: 1) To examine the
mpact of the 1997 IFG definition on CHD and CVD risk,
e compared FPG 110 to 125 mg/dl (6.1 to 6.9 mmol/l) to
referent group of FPG 110 mg/dl (6.1 mmol/l). 2) To
xamine the impact of the 2003 IFG definition on CHD
nd CVD risk, we compared FPG 100 to 125 mg/dl (5.6 to
.9 mmol/l) to a referent group of FPG 100 mg/dl (5.6
mol/l). 3) To directly compare the categorization and
erformance of the 1997 and 2003 IFG definitions, a
ulticategory model was created comparing both FPG 100
o 109 mg/dl (5.6 to 6.0 mmol/l) and 110 to 125 mg/dl (6.1
o 6.9 mmol/l) to a referent group of FPG 100 mg/dl
5.6 mmol/l). This model ensured that the same referent
roup would be used to compare individuals in the 100 to
09 mg/dl category with those in the 110 to 125 mg/dl
Abbreviations
and Acronyms
ADA  American Diabetes
Association
BMI  body mass index
CHD  coronary heart
disease
CI  confidence interval
CVD  cardiovascular
disease
FPG  fasting plasma
glucose
IFG  impaired fasting
glucose
IGT  impaired glucose
tolerance
OR  odds ratio
TIA  transient ischemic
attackategory.
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Impact of IFG on CVD January 22, 2008:264–70For analyses of diabetes prediction, individuals with
iabetes at each index examination were excluded and 3
imilar models (1 to 3 as described in the previous
aragraph) were constructed. Age-adjusted incidence
ates of CHD, CVD, and diabetes were calculated for
ach FPG group (17). Pooled logistic regression was used
o calculate the odds of developing CHD, CVD, or
iabetes over the follow-up intervals using SAS version
.1 (SAS Institute, Cary, North Carolina) (18). Pooled logistic
aseline Characteristics of Cohort*
Table 1 Baseline Characteristics of Cohort*
Characteristic
Women
(n  2,163)
Men
(n  1,895)
Age, yrs 48 (10) 49 (10)
Glucose, mmol/l 5.1 (1.2) 5.4 (1.4)
Current smoker, % 29 28
Body mass index, kg/m2 25.6 (5.4) 27.3 (3.9)
Systolic blood pressure, mm Hg 122 (18) 127 (16)
Hypertension treatment, % 14 16
Hypertension, % 26 35
Total/high-density lipoprotein
cholesterol, ratio
4.0 (1.4) 5.0 (1.6)
alues are mean (SD) or percent. *Data represent unique individuals based on first exam attended
nd is based on the sample free of cardiovascular disease (n  4,058).
4-Year Age-Adjusted Event Rates of CHD, CVD,and Diabetes by Baseline Glyc mic Status Cate
Table 2 4-Year Age-Adjusted Event Rates ofand Diabetes by Baseline Glycemic
Outcome <99
Any CHD event
Women
Events, n 39
Person-exams, n 5,563
4-year event rate (%) with 95% CI 0.8 (0.5–1.1)
Men
Events, n 106
Person-exams, n 3,960
4-year event rate (%) with 95% CI 2.9 (2.3–3.7)
Any CVD event
Women
Events, n 71
Person-exams, n 5,457
4-year event rate (%) with 95% CI 1.4 (1.1–1.9)
Men
Events, n 138
Person-exams, n 3,876
4-year event rate (%) with 95% CI 3.9 (3.2–4.8)
Diabetes
Women
Events, n 17
Person-exams, n 5,049
4-year event rate (%) with 95% CI 0.3 (0.2–0.6)
Men
Events, n 23
Person-exams, n 3,608
4-year event rate (%) with 95% CI 0.6 (0.4–1.0)CHD  coronary heart disease; CI  confidence interval; CVD  cardiovasculegression has been shown to provide estimates similar to those
enerated from time-dependent Cox regression analysis (19).
Models were initially age-adjusted and then adjusted for
ovariates for each end point. To compare the predictive
apacity of the 2003 versus 1997 IFG definition, we
xamined the c-statistics of all multivariable models. The
-statistic is a measure of model discrimination or concor-
ance between the predictions and outcomes (20). Crude
aplan-Meier curves were constructed using time to CVD
tratified by glycemic category (FPG 100 mg/dl; 100 to
09 mg/dl; 110 to 125 mg/dl; diabetes).
esults
he overall sample (n  4,058) consisted of 53% women,
nd the mean age was 49 years (Table 1).
mpact of the IFG definition on incident CHD and
VD. The 4-year rates of developing CHD are presented
n Table 2. There were 291 cases of incident CHD.
our-year CHD event rates among women were 1.3% (100
o 109 mg/dl), 2.3% (110 to 125 mg/dl), and 2.9% (diabe-
es), whereas corresponding rates in men were 2.9%, 3.0%,
nd 8.7%. The odds ratio for CHD in women for the 2003
efinition was 1.7 (95% confidence interval [CI] 1.0 to 3.0)
, CVD,
us Category
Multicategory Model (mg/dl)
100 to 109 110 to 125 Diabetes
14 12 13
882 365 318
.3 (0.7–2.2) 2.3 (1.3–4.3) 2.9 (1.6–5.3)
38 19 50
1,235 516 434
.9 (2.0–4.0) 3.0 (1.9–4.8) 8.7 (6.4–11.7)
19 18 20
850 352 299
.8 (1.1–2.9) 3.6 (2.2–5.9) 4.8 (3.0–7.6)
60 31 66
1,198 495 391
.6 (3.5–6.0) 5.0 (3.4–7.1) 12.5 (9.7–16.0)
31 87 —
780 317 —
.0 (2.7–6.0) 27.8 (21.6–35.1) —
—
52 92 —
1,129 442 —
.5 (3.3–6.1) 20.0 (15.8–25.1) —gory
CHD
Stat
1
2
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January 22, 2008:264–70 Impact of IFG on CVDnd for the 1997 definition was 2.2 (95% CI 1.1 to 4.4)
Table 3). In the multicategory model, women with FPG
10 to 125 mg/dl (6.1 to 6.9 mg/dl) had a 2.5-fold increased
dds ratio (OR) of CHD (95% CI 1.2 to 5.0, p  0.01),
hereas women with FPG 100 to 109 mg/dl (5.6 to 6.0
mol/l) had a nonsignificantly increased OR of CHD (OR
.4, 95% CI 0.7 to 2.7, p  0.30), suggesting that much of
he increase in CHD is driven primarily by those with FPG
10 to 125 mg/dl (6.1 to 6.9 mmol/l). Among women with
PG 110 to 125 mg/dl, the OR was similar to the OR for
HD in women with diabetes (OR 2.5, 95% CI 1.2 to 5.2,
 0.01). The c-statistic was essentially unchanged be-
ween models based on the 1997 versus the 2003 IFG
efinition (0.798 vs. 0.800, respectively).
In men, there was no significant difference in the OR of
eveloping CHD among those categorized by either the
997 IFG definition or the 2003 IFG definition (Table 3).
here was a significant gender interaction with incident
HD (p  0.04), indicating that the OR of developing
HD in women was significantly greater than for men.
Similar trends were observed for CVD (Table 4) (423
ncident events). The OR for CVD in women for the 2003
efinition was 1.4 (95% CI 0.9 to 2.1) and for the 1997
efinition was 2.1 (95% CI 1.2 to 3.6) (Table 4). In the
ulticategory model for women, no significantly increased
R was observed in the 100 to 109 mg/dl (5.6 to 6.0
mol/l) group, whereas significantly increased OR were
bserved among women with FPG 110 to 125 mg/dl (6.1 to
dds Ratios and 95% Confidence Intervals by Glucose Subgroupor 4-Year Incidence of CHD Ac ording to 1997 and 2003 IFG Defin
Table 3 Odds Ratios and 95% Confidence Intervals by Glucosefor 4-Year Incidence of CHD According to 1997 and 20
Multicategory Model (mg/dl)*
100 to 109 p Value 110 to 125 p Value
Women
Age-adjusted 1.7 (0.9–3.1) 0.11 3.1 (1.6–6.1) 0.001
MV-adjusted‡ 1.4 (0.7–2.7) 0.30 2.5 (1.2–5.0) 0.01
Men
Age-adjusted 1.0 (0.7–1.4) 0.92 1.0 (0.6–1.7) 0.91
MV-adjusted‡ 0.9 (0.6–1.4) 0.66 0.9 (0.5–1.5) 0.60
Referent group is100mg/dl (5.6 mmol/l). †Referent group is110mg/dl (6.1 mmol/l). ‡C
atio, current smoking, and body mass index.
CHD  coronary heart disease; IPG  impaired fasting glucose; MV  multivariable.
dds Ratios and 95% Confidence Intervals by Glucose Subgroupor 4-Year Incidence of Cardiovascular Disease According to 1997
Table 4 Odds Ratios and 95% Confidence Intervals by Glucosefor 4-Year Incidence of Cardiovascular Disease Accord
Multicategory Model, mg/dl*
100 to 109 p Value 110 to 125 p Value
Women
Age-adjusted 1.3 (0.8–2.1) 0.38 2.6 (1.5–4.5) 0.001
MV-adjusted‡ 1.1 (0.6–1.8) 0.84 2.1 (1.2–3.7) 0.01
Men
Age-adjusted 1.2 (0.9–1.6) 0.32 1.3 (0.8–1.9) 0.25
MV-adjusted‡ 1.1 (0.8–1.5) 0.51 1.0 (0.7–1.6) 0.85
Referent group is 5.6 mmol/l (100 mg/dl). †Referent group is 6.1 mmol/l (110 mg/dl)
moking, and BMI.
Abbreviations as in Table 3..9 mmol/l). The multivariable-adjusted c-statistics for the
997 and 2003 definitions were similar (0.785 vs. 0.787,
espectively).
In men, there was no significant difference in the OR of
eveloping CVD in those with IFG as categorized by either
he 1997 definition or 2003 definition; similar results were
bserved in the multicategory model (Table 4). The
ultivariable-adjusted c-statistics were identical for the 1997
nd 2003 definitions (0.763). The formal sex-interaction was
ot significant (p  0.19), although the trends observed were
verall similar to the CHD results. The results are presented as
aplan-Meier curves in Figure 1.
mpact of the IFG definition on incident diabetes. The
-year age-adjusted rates of developing diabetes by glycemic
ategory are presented in Table 2. Among women, the OR of
eveloping diabetes was elevated in multivariable-adjusted
odels for both the 1997 and 2003 definitions (Table 5).
mong men, the differences between the 1997 and 2003
efinitions were less striking than in women (Table 5).
econdary analyses. When glucose was modeled as a
ontinuous variable, for CVD, significant results were ob-
erved for women (p  0.007) as well as for men (p 
.0001). However, when individuals with diabetes were
xcluded from the models, results were no longer significant
women p  0.16; men p  0.89). For CHD, similar
ndings were observed (data not shown). Additional adjust-
ent for triglycerides in men did not result in any material
hanges to the results (data not shown).
s
roup
G Definitions
2003 IFG (mg/dl)* 1997 IFG† (mg/dl)
etes p Value 100 to 125 p Value 110 to 125 p Value
.1–7.6) 0.001 2.1 (1.3–3.5) 0.005 2.7 (1.4–5.2) 0.002
.2–5.2) 0.01 1.7 (1.0–3.0) 0.048 2.2 (1.1–4.4) 0.02
.2–4.6) 0.001 1.0 (0.7–1.4) 0.99 1.0 (0.6–1.7) 0.89
.7–3.8) 0.001 0.9 (0.6–1.3) 0.55 0.9 (0.5–1.5) 0.67
es: age, systolic blood pressure, hypertension treatment, total cholesterol/high-density lipoprotein
003 IFG Definitions
roup
1997 and 2003 IFG Definitions
2003 IFG, mmol/l* 1997 IFG, mmol/l†
etes p Value 100 to 125 p Value 110 to 125 p Value
.1–6.0) 0.001 1.7 (1.1–2.5) 0.01 2.5 (1.5–4.2) 0.001
.3–4.1) 0.007 1.4 (0.9–2.1) 0.16 2.1 (1.2–3.6) 0.01
.6–5.0) 0.001 1.2 (0.9–1.6) 0.19 1.2 (0.8–1.8) 0.35
.0–4.0) 0.001 1.1 (0.8–1.4) 0.56 1.0 (0.7–1.5) 0.98
riates: age, systolic blood pressure, hypertension treatment, total cholesterol/HDL ratio, currentition
Subg
03 IF
Diab
4.0 (2
2.5 (1
3.2 (2
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ovariatand 2
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rincipal findings. The 1997 and 2003 IFG definitions
re predictive of CHD in women but not in men. The odds
f developing CHD among women with IFG in the 110 to
25 mg/dl (6.1 to 6.9 mmol/l) range approach the risk
onferred by having diabetes. C-statistics were essentially
nchanged between the 1997 and 2003 IFG definitions,
uggesting no improvement in overall risk prediction when
ne uses the new IFG definition. For CVD, only the 1997
FG definition was associated with a statistically significant
ncreased odds among women, whereas no increased odds of
VD was observed in men for either IFG definition.
ltimately, however, men have greater absolute rates of
vents as compared with women. With respect to diabetes,
he 1997 IFG definition is associated with a greater risk of
eveloping diabetes compared with the 2003 IFG
efinition.
A possible explanation for the difference between CVD
nd CHD is that the CHD end point contains primarily
ard diagnoses that are known to be highly associated with
iabetes and pre-diabetes, such as myocardial infarction,
hereas CVD contains end points which are potentially
ore heterogeneous, such as intermittent claudication and
Figure 1 Kaplain-Meier Plots of CVD-Free Survival by Glycemic
CVD  cardiovascular disease; DM  diabetes mellitus; NGT  normal glucose to
dds Ratios and 95% Confidence Intervals for 4-Year Incidence ofxamining the 1997 and 2003 IFG D finitions in Age- and Multivar
Table 5 Odds Ratios and 95% Confidence Intervals for 4-Year IExamining the 1997 and 2003 IFG Definitions in Age-
Multicategory Model, mmol/l
5.6 to 6.0* p Value 6.1 to 6.9*
Women
Age-adjusted 12.4 (6.8–22.8) 0.001 114.5 (65.4–200.5)
MV-adjusted‡ 9.1 (4.9–17.0) 0.001 72.5 (40.5–129.8)
Men
Age-adjusted 7.2 (4.4–11.9) 0.001 38.5 (23.8–62.1)
MV-adjusted‡ 6.4 (3.9–10.6) 0.001 32.4 (20.0–52.6)Referent group is 5.6 mmol/l (100 mg/dl). †Referent group is 6.1 mmol/l (110 mg/dl). ‡Covar
Abbreviations as in Table 3.IA. Nonetheless, women in our sample with FPG 110 to
25 mg/dl (6.1 to 6.9 mmol/l) are at significantly increased
isk of both CHD and CVD.
n the context of current literature. Conflicting data exist
egarding the effect of nondiabetic fasting hyperglycemia on
ardiovascular risk. Whereas several studies have found that
he 1997 IFG definition is associated with significantly
ncreased risk for CVD (2,9,11,21), at least 5 studies have
hown no significantly increased risk for CVD with the
997 IFG definition (5,8,10,22,23).
Relatively fewer studies have examined the 2003 IFG cut
oint and its predictive capacity for CVD, and none have
emonstrated an increased risk (8–10,24). Kanaya et al. (9)
xamined data from the Heart and Estrogen/Progestin
eplacement Study, which enrolled women with known
oronary disease, grouped them by fasting glucose status,
nd followed them for CVD events, stroke, TIA, and CHF
ospitalization for an average of 6.8 years. They found that
omen with FPG 100 to 125 mg/dl (5.6 to 6.9 mmol/l)
ere at no increased risk for any end point as compared with
omen with normal levels of fasting glucose. In contrast, we
ound that women categorized by the 2003 IFG definition
o not have a statistically significant increased risk of CVD
gory
e; 100–109  100 to 109 mg/dl; 110–125  110 to 125 mg/dl.
tes-Adjusted Models
nce of Diabetes
ultivariable-Adjusted Models
2003 IFG Glucose Category,
mmol/l
1997 IFG Glucose Category,
mmol/l
alue 5.6 to 6.9* p Value 6.1 to 6.9† p Value
.001 33.9 (20.1–57.3) 0.001 42.3 (28.5–62.9) 0.001
.001 22.3 (13.0–38.1) 0.001 26.3 (17.4–39.8) 0.001
.001 14.6 (9.3–22.8) 0.001 14.9 (10.7–20.8) 0.001
.001 12.7 (8.1–20.0) 0.001 12.9 (9.3–18.1) 0.001Cate
lerancDiabeiable
ncide
and M
p V
0
0
0
0iates: age, body mass index, smoking.
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January 22, 2008:264–70 Impact of IFG on CVDOR 1.4, 95% CI 0.9 to 2.1) but do have significantly
ncreased odds of CHD (OR 1.7, 95% CI 1.0 to 3.0, p 
.048). A potential explanation for the differences in our
ndings may be the result of differences in our study sample,
hich included only individuals free of CVD at baseline,
hich is especially important when comparing our findings
o those of Kanaya et al. (9), who used a sample of women
ith pre-existing CVD, and followed their participants for
ew events.
In a recent publication from the Hoorn Study in which
articipants (n 1,428) were categorized according to 1997
nd 2003 criteria based on OGTT measured in 1989 and
996 with 10-year follow-up for all-cause and CVD mor-
ality, there was no significant increased risk for CVD unless
articipants developed diabetes (12). These data are dis-
inctly incongruent with our current findings, possibly in
art because of the lack of gender-specific analyses in the
oorn study.
The Hoorn investigators used oral glucose tolerance
esting to diagnose impaired fasting glucose as compared
ith our use of FPG, which may also be pertinent to
nderstanding why our findings differed. However, re-
earchers using data from the Atherosclerosis Risk in
ommunities Study recently have confirmed that there is
oor congruence between IFG (defined as 100 to 125
g/dl; 5.6 to 6.9 mmol/l) and impaired glucose tolerance
IGT). They also demonstrate that neither IFG nor IGT are
ssociated with an increased risk of all-cause mortality or
ncident CHD after a median follow-up of 6.3 years in
ully-adjusted models (25). Therefore, we believe that our
ndings using FPG to diagnose IFG is an acceptable and
linically applicable method by which to conduct these analy-
es. Finally, a recent study from a community-based medical
enter examined CVD risk factor prevalence and prevalent
VD events among individuals with the 1997 as compared
ith the 2003 IFG definition (26) and found that the 2003
efinition was not associated with an elevated level of CVD
isk factors or CVD as compared to the 1997 definition.
ender differences. For any given glycemic category,
omen had greater relative odds of CHD and CVD as
ompared with men, although men had greater absolute
vent rates for cardiovascular disease. In fact, the cardiovas-
ular disease event rates and odds ratios for women in the
10 to 125 mg/dl group were similar to those for women
ith diabetes in our sample. These findings build upon
hose from a recent meta-analysis that included more than
3,000 women and 172,000 men in examining nondiabetic
yperglycemia as a risk factor for CVD; results demonstrate
hat the risk of CVD events was markedly greater in cohorts
hat included women (27). However, gender-specific data
or women in this meta-analysis were not presented. Taken
ogether with our findings, CVD and diabetes risk in
omen may occur at lower glucose thresholds as compared
ith men, which raises several potentially interesting ques-
ions. Whether gender differences are due to intrinsic
iologic differences or differences in risk factor management ts uncertain. These differences also raise the question of
hether gender-specific cut points for impaired fasting
lucose should exist.
mplications. In the absence of a clear glucose threshold
hat is predictive of CVD, the debate continues regarding
hat should define IFG to maximize sensitivity and speci-
city for predicting cardiovascular events. In examining the
ffect of IFG categorization with respect to cardiovascular
isease, we uncovered gender differences, raising the ques-
ion of whether a lower glycemic threshold should be used
o diagnose IFG or diabetes in women. It is important to
emember, however, that men have a greater absolute rate of
vents as compared with women. Further, IFG is not a
HD risk-equivalent. In addition, whether the effect of
dentifying individuals with this diagnosis in clinical practice
ncourages lifestyle modification including weight loss and
ncreased physical activity is uncertain. Fasting blood sugar
s often associated with other adverse CVD risk factors and
ay serve to identify patients with hypertension and dys-
ipidemia. Finally, it is uncertain whether identifying an
ndividual with IFG results in aggressive CVD risk factor
odification; randomized clinical trials among individuals
ith IFG would be necessary to assess this.
trengths and study limitations. The strength of our
nalysis lies in our population-based cohort and long-term
ollow-up. We assessed the glycemic status of our partici-
ants every 4 years and were able to remove those who
eveloped incident diabetes from the IFG category, which is
articularly important when trying to understand the risk of
ardiovascular disease associated with IFG independently of
eveloping diabetes.
Our study has several limitations which must be acknowl-
dged. Oral glucose tolerance testing was not available at
ach index examination cycle, thereby precluding comment
n how the 1997 and 2003 IFG definitions compare with
GT for prediction of CVD. Further, this unavailability
ay have resulted in cases of undiagnosed diabetes in our
xposure group. However, the primary point of our paper is
o analyze the current ADA recommendations for IFG, and
urrent guidelines do not recommend the routine use of oral
lucose tolerance testing (28).
Next, although we found no increased risk in men for
HD and CVD, we examined short-term risk, and appli-
ation to long-term risk, which allows for transition to
iabetes over many years of follow-up, is uncertain. How-
ver, the consideration of short-term risk is congruent with
he ADA’s recommendation that all individuals over 45
ears of age be screened for diabetes every 3 years and even
ore frequently if additional risk factors are present (29).
hird, the Framingham Heart Study at its inception in
948 included only white participants. Therefore, the gen-
ralizability to other ethnic groups is uncertain. However,
he Framingham risk score has been validated in other ethic
roups and has been found to be applicable in other
opulations (30,31). Although we used data from our study
hat spans several decades, we do not believe that temporal
t
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Impact of IFG on CVD January 22, 2008:264–70rends would have an important effect on our results,
ecause we have previously shown that the relative risk
etween cardiovascular disease and diabetes has not changed
ver time (32). Finally, we only evaluated cardiovascular
omplications of IFG and diabetes and were not able to
ssess retinopathy, neuropathy, and nephropathy, which
ay yield different findings.
onclusions
ur data suggest that for prediction of CHD and CVD
vents, neither IFG definition identifies a group of men at
ncreased short-term risk. In women, there is a significantly
ncreased risk of CHD in the 2003 IFG group, but this risk
s driven primarily by the high event rate in participants with
PG 110 to 125 mg/dl (6.1 to 6.9 mmol/l). In comparing
omen and men, for any given prediabetic category, women
ave a greater relative risk of CHD than men. The 2003
FG definition does not offer substantive advantages over
he 1997 definition for prediction of CVD or diabetes.
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